Published in Kidney Int on March 01, 2004
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) | NCT00338260
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care (2010) 4.67
Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) (2010) 2.94
Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ (2012) 2.39
Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther (2006) 1.80
Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. Intern Emerg Med (2007) 1.72
Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res (2014) 1.49
Associations of serum uric acid levels with arterial wave reflections and central systolic blood pressure. Int J Cardiol (2013) 1.44
Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant (2008) 1.31
Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med (2009) 1.21
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep (2013) 1.20
Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol (2008) 1.20
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol (2006) 1.09
Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med (2012) 1.08
Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol (2013) 1.02
Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol (2011) 1.01
Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum (2012) 1.00
Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. Diabetes Care (2010) 0.94
Hyperuricemia and incident heart failure. Circ Heart Fail (2009) 0.92
Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T (2011) 0.92
Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS One (2014) 0.91
Relationship between serum uric acid and internal carotid resistive index in hypertensive women: a cross-sectional study. BMC Cardiovasc Disord (2012) 0.89
Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. Medicine (Baltimore) (2015) 0.88
Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med (2015) 0.87
Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Dis Markers (2015) 0.87
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol (2009) 0.86
Racial/ethnic and sex differences in the relationship between uric acid and metabolic syndrome in adolescents: an analysis of National Health and Nutrition Survey 1999-2006. Metabolism (2011) 0.86
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients? Int J Nephrol Renovasc Dis (2010) 0.86
Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel) (2016) 0.84
Relationship Between Hyperuricemia and Cardiovascular Disease Risk Factors in a Chinese Population: A Cross-Sectional Study. Med Sci Monit (2015) 0.84
Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res (2016) 0.83
Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. Int J Clin Pract (2007) 0.83
Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J Surg (2007) 0.82
Optical method for cardiovascular risk marker uric acid removal assessment during dialysis. ScientificWorldJournal (2012) 0.81
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed) (2009) 0.81
Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag (2011) 0.80
Determinants of vascular function in patients with chronic gout. J Clin Hypertens (Greenwich) (2010) 0.80
Association of Serum Uric Acid with Cardiovascular Disease in Taiwanese Patients with Primary Hypertension. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.80
Serum uric acid and cardiovascular disease. Maedica (Buchar) (2010) 0.79
The association between serum uric acid and renal damage in a community-based population: the Takahata study. Clin Exp Nephrol (2012) 0.79
Stroke in chronic kidney disease: prevention and management. Clin J Am Soc Nephrol (2008) 0.78
Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev (2013) 0.78
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vasc Health Risk Manag (2007) 0.77
Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res (2015) 0.77
Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study. Nutr J (2015) 0.76
A cross-sectional analysis of the relationship between uric acid and coronary atherosclerosis in patients with suspected coronary artery disease in China. BMC Cardiovasc Disord (2014) 0.76
Hepatic iron in hemodialysis patients. Kidney Int (2004) 0.76
Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. Int J Clin Exp Pathol (2015) 0.75
Prognostic Value of Serum Uric Acid in Patients on the Waiting List before and after Renal Transplantation. Int J Nephrol (2015) 0.75
Opposing effects of sodium intake on uric acid and blood pressure and their causal implication. J Am Soc Hypertens (2016) 0.75
Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. Oman Med J (2012) 0.75
Serum uric acid levels and cardiovascular disease: the Gordian knot. J Thorac Dis (2016) 0.75
Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis. CEN Case Rep (2014) 0.75
Association between serum uric acid, urinary albumin excretion, and glycated hemoglobin in Type 2 diabetic patient. Niger Med J (2016) 0.75
Increased childhood BMI is associated with young adult serum uric acid levels: a linkage study from Japan. Pediatr Res (2016) 0.75
Hyperuricemia and risk of increased arterial stiffness in healthy women based on health screening in Korean population. PLoS One (2017) 0.75
High serum uric acid levels may increase mortality and major adverse cardiovascular events in patients with acute myocardial infarction. Saudi Med J (2017) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Bariatric surgery and long-term cardiovascular events. JAMA (2012) 7.11
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01
The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87
Glycemic control and excess mortality in type 1 diabetes. N Engl J Med (2014) 6.39
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med (2012) 6.19
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15
Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol (2013) 6.12
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol (2007) 4.49
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil (2003) 4.25
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78